DEF: Karyopharm Seeks Major Share Increase for Future Capital

Karyopharm Therapeutics Inc. will hold a special stockholder meeting on February 18, 2026, to vote on a proposal to significantly increase its authorized common stock to facilitate future capital raising and strategic initiatives.

Summary

• Karyopharm Therapeutics Inc. is calling a Special Meeting of Stockholders for February 18, 2026, at 9:00 a.m. Eastern Time, to be held exclusively online.
• The primary proposal (Proposal 1) is to amend the Restated Certificate of Incorporation to increase the total authorized shares of capital stock from 58,333,333 to 111,000,000 and authorized common stock from 53,333,333 to 106,000,000.
• As of December 23, 2025, 42,747,918 shares of common stock were issued or reserved for issuance, leaving only 10,585,415 unreserved shares available for future issuance.
• The company states it is nearing the limit of its currently authorized common stock, which restricts its ability to raise capital for business plans and strategic initiatives.
• The increase is intended to provide flexibility for future corporate finance, equity issuance, business development, equity compensation, and other general corporate purposes.
• The Board of Directors unanimously recommends voting FOR the Authorized Shares Proposal and FOR the Adjournment Proposal.
• A second proposal (Proposal 2) seeks approval to adjourn the Special Meeting if necessary to solicit additional proxies for the Authorized Shares Proposal.
• Only stockholders of record as of December 29, 2025, are entitled to vote, with 18,310,283 shares of common stock outstanding on that date.
• The company expects to report top-line data from its Phase 3 SENTRY trial in myelofibrosis in March 2026 and Phase 3 XPORT-EC-042 trial in endometrial cancer in mid-2026.
• Existing cash, cash equivalents, investments, and cash flows are expected to fund current operating plans into the second quarter of 2026.

Sentiment

Score: 4

Explanation: The filing indicates a critical need for future capital to sustain operations and advance its pipeline, explicitly mentioning 'going concern' risk. While the proposed share increase provides necessary flexibility, it also signals potential significant dilution for existing shareholders. The proactive step to secure authorization is positive for long-term viability, but the underlying necessity highlights financial pressure.

Positives

• The proposed increase in authorized shares provides Karyopharm with greater flexibility to raise additional capital and pursue strategic transactions.
• Having additional authorized shares available before reporting key clinical trial data in 2026 may allow the company to take advantage of favorable market conditions for capital raising or strategic partnerships.
• The ability to raise capital is crucial for funding ongoing clinical development, potential regulatory approvals, and commercialization of selinexor for myelofibrosis or endometrial cancer, pending positive data.

Negatives

• The company explicitly states that its ability to continue as a going concern depends on its ability to raise additional capital in the future, indicating a near-term funding requirement.
• The significant increase in authorized shares (nearly doubling) suggests a potential for substantial future dilution for existing stockholders.
• If the proposal is not approved, the company's ability to raise capital through future equity offerings would be severely limited to 10,585,415 shares, which may be insufficient to meet cash needs.

Risks

• The issuance of additional shares of common stock may have a dilutive effect on earnings per share, stockholders' equity, and voting rights.
• Future sales of substantial amounts of common stock, or the perception of such sales, could adversely affect the prevailing market price of the common stock or limit the company's ability to raise additional capital.
• The Authorized Shares Proposal could, under certain circumstances, have an anti-takeover effect by allowing the Board to issue shares to friendly parties, potentially discouraging unsolicited takeover attempts and limiting stockholder opportunities to sell shares at a premium.
• Failure to approve the proposal may prevent the company from pursuing effective strategies to access capital in public and private markets, negatively affecting its ability to continue as a going concern.
• The company's ability to achieve business objectives and continue as a going concern depends on its ability to raise additional capital in the future.

Future Outlook

Karyopharm expects to report top-line data from its Phase 3 SENTRY trial in myelofibrosis in March 2026 and from its Phase 3 XPORT-EC-042 trial in endometrial cancer in mid-2026. The company anticipates filing a new universal shelf registration statement before May 5, 2026, to replace the current one. The ability to achieve business objectives and continue as a going concern depends on raising additional capital in the future.

Management Comments

• Richard Paulson, President, Chief Executive Officer and Director, stated, 'Whether or not you plan to attend the Special Meeting online, we urge you to submit a proxy to vote your shares by submitting your proxy over the Internet or by telephone, or by completing, dating, signing and returning the enclosed proxy card in the accompanying envelope.'

Industry Context

This filing is a procedural corporate action to enable future financing, which is common for biotechnology companies, especially those with significant R&D pipelines and upcoming clinical trial readouts. The need to raise capital to fund operations and prepare for potential commercialization is a typical challenge in the industry, particularly for companies nearing critical data milestones.

Comparison to Industry Standards

• NA

Corporate Governance

Stakeholder Impact

• **Shareholders**: Potential for significant dilution if new shares are issued, but also potential for increased company stability and growth if capital is effectively deployed. Voting rights could be diluted. The proposal could also have anti-takeover implications.
• **Employees**: Increased job security and potential for continued operations if the company successfully raises capital to fund its plans.
• **Creditors**: Enhanced ability for the company to meet its financial obligations if it can successfully raise capital, potentially reducing credit risk.
• **Customers/Patients**: Continued development and potential commercialization of selinexor for myelofibrosis and endometrial cancer, leading to potential new treatment options.

Next Steps

• Hold a Special Meeting of Stockholders on February 18, 2026, to vote on the Authorized Shares Proposal and the Adjournment Proposal.
• If approved, the Board reserves the right to abandon the Authorized Shares Charter Amendment if it determines it is no longer in the company's best interest.
• Publish final voting results in a current report on Form 8-K within four business days after the Special Meeting.
• Report top-line data from the Phase 3 SENTRY trial in myelofibrosis in March 2026.
• Report top-line data from the Phase 3 XPORT-EC-042 trial in endometrial cancer in mid-2026.
• File a new universal shelf registration statement before May 5, 2026, to replace the current one.

Key Dates

Keywords

Karyopharm Therapeutics, KPTI, Authorized Shares, Capital Raise, Stockholder Meeting, Proxy Statement, Dilution, Corporate Governance, SEC Filing, Biotechnology, Pharmaceuticals, Clinical Trials, Selinexor